Brainstorm cell therapeutics announces first quarter 2022 financial results and provides a corporate update

Brainstorm continues to gain insights and perspectives from leading als experts as it seeks the optimal path forward to provide broad patient access to nurown® strengthened executive team in preparation for anticipated growth and corporate development, with the appointment of netta blondheim-shraga, phd, as vp of research & development and antal pearl-lendner, avd, as chief legal counsel conference call and webcast at 8:00 a.m. eastern time today new york , may 16, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the first quarter ended march 31, 2022 and provided a corporate update.
BCLI Ratings Summary
BCLI Quant Ranking